Gallacher Capital Management LLC Increases Position in Lantheus Holdings, Inc. $LNTH

Gallacher Capital Management LLC grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 228.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,388 shares of the medical equipment provider’s stock after purchasing an additional 9,317 shares during the quarter. Gallacher Capital Management LLC’s holdings in Lantheus were worth $687,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Janney Montgomery Scott LLC lifted its position in Lantheus by 17.5% during the second quarter. Janney Montgomery Scott LLC now owns 31,388 shares of the medical equipment provider’s stock worth $2,569,000 after buying an additional 4,677 shares in the last quarter. Truist Financial Corp increased its stake in shares of Lantheus by 6.1% in the 2nd quarter. Truist Financial Corp now owns 6,696 shares of the medical equipment provider’s stock worth $548,000 after acquiring an additional 382 shares during the last quarter. KLP Kapitalforvaltning AS increased its stake in shares of Lantheus by 12.5% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 26,023 shares of the medical equipment provider’s stock worth $2,130,000 after acquiring an additional 2,900 shares during the last quarter. Galvin Gaustad & Stein LLC purchased a new position in shares of Lantheus during the 2nd quarter worth $11,899,000. Finally, MGO One Seven LLC acquired a new position in shares of Lantheus during the 2nd quarter valued at about $274,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Performance

Shares of LNTH stock opened at $65.93 on Thursday. The firm’s 50 day moving average price is $65.35 and its 200-day moving average price is $59.74. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.29. The firm has a market cap of $4.37 billion, a P/E ratio of 27.70 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share for the quarter, meeting the consensus estimate of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The firm had revenue of $384.01 million during the quarter, compared to the consensus estimate of $363.42 million. During the same quarter last year, the firm earned $1.70 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Mizuho raised their price objective on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Truist Financial lifted their price target on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Finally, The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.